About the Company
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKUS News
Gene therapy at CHOP allowed a deaf boy to hear. But some deaf people object to the treatment.
The version administered at CHOP was manufactured by Akouos Inc., a subsidiary of Eli Lilly. Reaching the cochlea But the ...
Hearing loss treatment sees promising breakthrough with gene therapy
Eli Lilly and Company subsidiary Akouos has reported encouraging initial data from the Phase I/II AK-OTOF-101 clinical trial of its investigational gene therapy, AK-OTOF, for genetic hearing loss.
Pivotal bioVenture Partners Fund I, L.P.'s Net Worth
This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Entasis Therapeutics Holdings Inc., and Akouos, Inc..
NOVARTIS AG's Net Worth
NOVARTIS AG has an estimated net worth of $1.34 Billion. This is based on reported shares across multiple companies, which include Cellular Biomedicine Group, Inc., Poseida Therapeutics, Inc ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Tesla, Inc. (TSLA)
Tesla will report Q1 earnings after the bell on Tuesday, giving a much-needed update on the EV maker’s current and future prospects as investor sentiment slides. Tesla (TSLA) is asking ...
‘Food, Inc. 2’ Review: A Second Course
Share full article “Food, Inc. 2,” directed by Robert Kenner and Melissa Robledo, begins by describing how the last few years have shown the risks of letting a handful of mega-suppliers ...
Nike Inc. Cl B
Under Armour Inc. Cl C 1.39% $2.9B Under Armour Inc. Cl A 0.74% $2.9B ...
Macy's, Inc. (M)
Vanguard Small Cap Value Index Fund 4.81M Dec 31, 2023 1.75% 89,121,520 Vanguard Extended Market Index Fund 4.05M Dec 31, 2023 1.47% 75,050,783 Avantis U.S. Small Cap Value Fund 3.32M Dec 31, 2023 ...
Loading the latest forecasts...